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ARTICLE
A Novel Dominant Mutation in Plakoglobin Causes
Arrhythmogenic Right Ventricular Cardiomyopathy
Angeliki Asimaki, Petros Syrris, Thomas Wichter, Paul Matthias, Jeffrey E. Saffitz,
and William J. McKenna
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited disorder associated with arrhythmias and
sudden death. A recessive mutation in the gene encoding plakoglobin has been shown to cause Naxos disease, a cardio-
cutaneous syndrome characterized by ARVC and abnormalities of hair and skin. Here, we report, for the first time, a
dominant mutation in the gene encoding plakoglobin in a German family with ARVC but no cutaneous abnormalities.
The mutation (S39_K40insS) is predicted to insert an extra serine residue at position 39 in the N-terminus of plakoglobin.
Analysis of a biopsy sample of the right ventricle from the proband showed markedly decreased localization ofplakoglobin,
desmoplakin, and connexin43 at intercalated discs in cardiac myocytes. A yeast-two-hybrid screen revealed that the
mutant protein established novel interactions with histidine-rich calcium-binding protein and TGFb induced apoptosis
protein 2. Immunoblotting and confocal microscopy in human embryonic kidney 293 (HEK293) cell lines transfected
to stably express either wild-type or mutant plakoglobin protein showed that the mutant protein was apparently ubi-
quitylated and was preferentially located in the cytoplasm, suggesting that the S39_K40insS mutation may increase
plakoglobin turnover via proteasomal degradation. HEK293 cells expressing mutant plakoglobin also showed higher rates
of proliferation and lower rates of apoptosis than did cells expressing the wild-type protein. Electron microscopy showed
smaller and fewer desmosomes in cells expressing mutant plakoglobin. Taken together, these observations suggest that
the S39_K40insS mutation affects the structure and distribution of mechanical and electrical cell junctions and could
interfere with regulatory mechanisms mediated by Wnt-signaling pathways. These results implicate novel molecular
mechanisms in the pathogenesis of ARVC.
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Arrhythmogenic right ventricular cardiomyopathy (ARVC)
is a heart-muscle disorder characterized by fibrofatty re-
placement of cardiac myocytes. Right ventricular features
predominate, but left ventricular involvement can also
arise with disease progression and may be the dominant
presentation. The main clinical complications are arrhyth-
mias, heart failure, and sudden cardiac death.1
ARVC exhibits age-related expression. Penetrance is low
(∼30%) and often incomplete. There is phenotypic vari-
ation in both its presentation and its clinical course, even
within affected individuals from the same family. Clinical
diagnosis relies on demonstration of structural, function-
al, and electrophysiological abnormalities, which reflect
the electrical and mechanical alterations in the right ven-
tricle. Despite thorough investigation, a definitive diagno-
sis is often problematic. This diagnostic uncertainty is a
barrier to disease-gene mapping and identification.1 ARVC
is familial in 30%–50% of cases and is typically inherited
in an autosomal dominant fashion, although recessive
forms are recognized. One of these, Naxos disease (MIM
#601214), a cardiocutaneous syndrome characterized by
ARVC, nonepidermolytic palmoplantar keratoderma, and
woolly hair, is caused by a 2-bp deletion in the gene en-
coding plakoglobin (PK2157del2 [MIM *173325]).2
Plakoglobin is a major component of cell-cell adhesion
complexes, which are abundant in many tissues. It is also
a signaling molecule with roles in desmosome assembly
and development and in regulation of gene expression.3
Mutations in other desmosomal genes have also been im-
plicated in the pathogenesis of ARVC, including those en-
coding desmoplakin (MIM125647),4 plakophilin-2 (MIM
*602861),5 desmoglein-2 (MIM *125671),6 and desmocol-
lin-2 (MIM *125645).7,8 It is now widely believed that
ARVC is a disease caused by abnormal cell-cell adhesion
due to defects in desmosomes, intercellular adhesive junc-
tions that anchor cytoskeletal filaments at membrane-as-
sociated plaques. Desmosomes provide tissues with me-
chanical strength and are most abundant in tissues ex-
posed to high levels of mechanical stress, such as the ep-
idermis and cardiac muscle.9
Here, we report a novel mutation (S39_K40insS) in the
gene encoding plakoglobin that has been identified in an
ARVC-affected patient of German origin. We also provide
evidence derived from in vitro experiments that points
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Figure 1. Electropherograms showing wild-type (A) and mutant
(B) sequences of exon 2 of the gene encoding plakoglobin. The
position of the insertion is marked with an arrow. C, Pedigree of
family with ARVC. Squares denote males; circles denote females.
The gray symbol denotes a deceased individual who did not un-
dergo clinical evaluation but who was presumed to have been
affected. Affected individuals fulfilled the Task Force criteria for
ARVC.10 The index patient is marked with an arrow.
toward its potential mechanism of pathogenesis. To our
knowledge, S39_K40insS is the first dominant ARVC-caus-
ing mutation in plakoglobin to be reported to date.
Methods and Material
Clinical Screening
Patients suspected of having ARVC are evaluated at a consultant-
led ARVC clinic at the University Hospital of Mu¨nster. All patients
undergo detailed noninvasive evaluation, including two-dimen-
sional and Doppler echocardiography, 12-lead and signal-aver-
aged electrocardiography, 24-h Holter monitoring, and exercise
testing. Patients whose noninvasive-test results indicate life-
threatening ventricular tachyarrhythmias and/or the presence of
ARVC also undergo magnetic resonance imaging, right ventric-
ular contrast angiography, endomyocardial biopsy, and invasive
electrophysiological study, for further characterization of disease
expression and risk stratification.
Genetic Screening and Mutation Identification
The proband in this study (II:1 in fig. 1) was part of a larger cohort
of ARVC-affected patients who were investigated for mutations
in desmosomal genes associated with the disorder. DNA was ex-
tracted from blood samples and was amplified by PCR. PCR prod-
ucts were analyzed by agarose-gel electrophoresis and were am-
plified for direct sequencing. All participants gave informed con-
sent for genetic screening.
Tissue Acquisition and Immunohistochemistry
A right ventricular biopsy sample obtained from the proband (II:
1) during a right heart catheterization was immunostained using
methods that were validated in a previous study.11 Myocardial
specimens obtained at autopsy from three age-matched indi-
viduals who had no clinical history or pathological evidence of
heart disease were subjected to the same staining protocol and
were used as controls. Primary antibodies included polyclonal
rabbit anti-connexin43 (Cx43) (Zymed), monoclonal mouse anti-
plakoglobin (Sigma), polyclonal rabbit anti-desmoplakin (Sero-
Tec), monoclonal mouse anti-N-cadherin (Sigma), and monoclo-
nal mouse anti-plakophilin-2 (Biodesign) antibodies. Immuno-
stained preparations were analyzed by laser-scanning confocal
microscopy (Sarastro Model 2000 [Molecular Dynamics]) as de-
scribed elsewhere.11
Yeast-Two-Hybrid Screening
This method was used to detect ESTs from a human heart cDNA
library that bound wild-type or mutant plakoglobin. The S.c.
EasyComp Transformation Kit (Invitrogen) was used to generate
competent Saccharomyces cerevisiae cells and to transform them
with the plasmid of interest, according to the manufacturer’s in-
structions. Recombinant pDEST32 (bait, 10 mg) and pEXP-AD502
(library, 10 mg) were introduced into Library-Scale Frozen Com-
petent MaV203 yeast cells (Invitrogen), which were subsequently
plated on 10-cm plates with synthetic complete medium lacking
leucine and tryptophan to estimate the total number of trans-
formants. Transformants were selected and tested for lacZ with
use of a b-galactosidase colony–lift assay. Plasmids were extracted
from the yeast cells and were used to transform competent Esch-
erichia coli, which were then plated on antibiotic-selective plates.
DNA (500–600 ng) was used to set up a sequencing reaction, and
the obtained data were compared against the Human Reference
DNA Sequences by a sequence similarity–searching computer pro-
gram (BLAST).
In Vitro Protein-Binding Assay
BL21 star cells (Invitrogen) were transfected with recombinant
plasmids constructed for the expression of glutathione S-trans-
ferase (GST) as well as the GST-fused N-terminal, central, and C-
terminal domains of the histidine-rich calcium-binding protein
(HRC-BP [MIM *142705]). Expression of the recombinant con-
struct was induced by isopropyl-b-D-thiogalactopyranoside (IPTG).
Cell pellets obtained after centrifugation were resuspended in Tris
buffer (50 mM Tris-HCl [pH 8.0], 0.1% Triton, and 100 mM NaCl,
supplemented with protease inhibitors), were sonicated, and were
centrifuged, and the supernatant fraction was mixed with G-
Sepharose beads. Coomassie-blue staining was used to visualize the
purified protein fragments. Pellets of stably transfected human em-
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bryonic kidney 293 (HEK293) cells were resuspended in 0.1%
Tween in PBS and and were sonicated and centrifuged. Aliquots
of the supernatant fractions containing 0.5 mg of protein were
added to HRC-fragment– or GST-only–bound Sepharose beads,
were rocked, and were centrifuged. The beads were washed in
0.1% Tween in PBS and were loaded on a Tris-glycine gel, and a
western blot for plakoglobin expression was performed as de-
scribed in the “Western Immunoblotting” section.
Restriction Enzyme–Based Cloning
A recombination reaction of pDONR vector (Invitrogen) and plak-
oglobin cDNA bearing Gateway-compatible attB sites was per-
formed using the BP clonase enzyme. The pcDNA4/His-Max vec-
tor (Invitrogen) was converted to a Gateway-compatible form
with use of a Gateway vector–conversion reagent system kit (Invi-
trogen). Plakoglobin was subcloned from the recombinant p-
DONR plasmid into the pcDNA4/His-Max vector and the p-
DEST32 vector, with use of the LR clonase enzyme. Plakoglobin
was subcloned into the pcDNA5/FRT/TO vector (Invitrogen) with
use of the BamHI and EcoRV restriction sites and into the pGFP-
C3 vector (Clontech) with use of the BamHI and EcoRI restriction
sites. TGFb-induced apoptosis protein 2 (TAIP-2) cDNA (pur-
chased from Biosearch Technologies) was cloned into the PCR
blunt TOPO vector with use of the Zero Blunt TOPO PCR Cloning
Kit (Invitrogen) and was subcloned into the pcDNA V5 His 3.1
vector (Invitrogen) with use of the EcoRI restriction sites. Ligation
was performed with T4 ligase.
Site-Directed Mutagenesis
A plakoglobin construct bearing the S39_K40insS mutation was
generated by subjecting recombinant pcDNA5/FRT/TO, pcDNA4/
His-Max, pDEST32, and pGFP-C3 vectors to site-directed muta-
genesis, with use of Pfu DNA polymerase enzyme, according to
the manufacturer’s instructions.
Generation of Stably Transfected Cell Lines
pcDNA5/FRT/TO constructs expressing wild-type and mutant
plakoglobin were introduced in HEK293 cells (Invitrogen) with
use of a polyfect transfection reagent. Recombinants were selected
with blasticidin (15 mg/ml) and hygromycin (100 mg/ml) and were
induced to express the exogenous proteins by incubation in tet-
racycline (100 ng/ml).
Western Immunoblotting
Cell cultures were harvested, were washed with PBS, and were
lysed in radioimmunoprecipitation buffer (50 mM Tris-HCl [pH
7.4], 1% NP-40, 0.25% Na deoxycholate, 150 mM NaCl, 1 mM
EDTA, 1 mM Na3VO4, 1 mM NaF, and protease-inhibitor cocktail).
Cell lysate samples were loaded on Tris-glycine gels, were electro-
phoresed, were transferred to nitrocellulose membranes, and were
incubated, first with a primary antibody (anti-plakoglobin, 1:500
[Santa Cruz Biotech], or anti-ubiquitin, 1:5,000 [AbCam]) and
then with a horseradish peroxidase–linked anti-mouse immuno-
globulin G. Blots were developed with ECL reagents (Amersham).
Transient Transfection and Coimmunoprecipitation
HEK293 cells were transiently transfected using a polyfect reagent
to express either wild-type or mutant plakoglobin constructs that
were tagged with green fluorescent protein (GFP) to facilitate
identification of the expressed protein by fluorescence micros-
copy. These cells were also used in immunoprecipitation assays.
In preparation for immunoprecipitation studies, cells were grown
to confluence and were harvested as described in the “Western
Immunoblotting” section. The cell pellets were resuspended in
immunoprecipitation buffer (25 mM HEPES-KOH [pH 7.5], 150
mM KCl, 1 mM EDTA, 12.5 mM MgCl2, and 0.1% NP-40), were
sonicated, and were centrifuged at 16,110 g at 4C for 5 min.
Aliquots of the supernatant fraction (equivalent to 2 mg of pro-
tein) were mixed with an epitope-specific antibody and protein
G-Sepharose beads slurry in IP buffer and were rotated overnight
at 4C. After centrifugation, the supernatant was discarded, and
the pellet was washed and resuspended in IP buffer. A western
blot was performed using the other epitope-specific antibody as
described in the “Western Immunoblotting” section.
Cell-Proliferation Assay
Proliferation rates in HEK293 cells expressing either wild-type
or mutant plakoglobin were measured using the CellTiter 96
Cell proliferation assay (Promega) according to the manufac-
turer’s instructions.
Caspase-3 Assay
Cells were grown in 10-cm dishes, were harvested, and were re-
suspended in cell lysis buffer (10 mM HEPES [pH 7.4], 2 mM
EDTA, 0.1% CHAPS, 5 mM dithiothreitol, 1 mM phenylmethyl-
sulfonyl fluoride, 10 mg/ml pepstatin A, 10 mg/ml aprotinin, and
20 mg/ml leupeptin). After repeated freeze-thaw cycles, lysates
were centrifuged, and aliquots of the supernatant fraction equiv-
alent to 40 mg of protein were obtained. Caspase-3 activity was
measured using the CaspACE assay system (Promega) according
to the manufacturer’s instructions.
Electron Microscopy of Tissue Culture Cells
Cells were grown to confluence on glass coverslips and were then
fixed for 24 h in 2% glutaraldehyde in 0.1 mM cacodylate buffer
(pH 7.4). Fixed cells were postfixed in 1% OsO4, were dehydrated
in ethanol, and were embedded in Spurr’s low-viscosity epoxy
resin. Ultrathin sections were cut in a plane parallel to the plane
of the culture dish and were examined with a JEOL 100SX trans-
mission electron microscope. The number and size of individual
desmosomes were measured in 10 randomly selected electron
micrographs (final magnification, 9,000#) of cells stably express-
ing wild-type or mutant plakoglobin.
Statistical Analysis
Data are expressed as mean SD and were analyzed by Student’s
t test. Statistical significance was defined as .P ! .05
Results
Mutation in Plakoglobin
The proband was initially screened for mutations in plako-
globin, desmoplakin, and plakophilin-2. We identified an
insertion of 3 bases in plakoglobin (118_119insGCA) in
one family (fig. 1). This mutation has not been reported
elsewhere. It does not disrupt the frame of translation but
is predicted to result in the insertion of an additional ser-
ine residue at amino acid position 39 within the N-ter-
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Figure 2. Microscopic appearance of the cardiac biopsy sample
from the proband (by Masson’s trichrome stain).
Figure 3. Confocal immunofluorescence microscopy analysis of
control and proband left ventricular myocardium, showing the
amount of immunoreactive signal for selected junctional proteins
at intercalated disks.
minal domain of plakoglobin (S39_K40insS). It also does
not disrupt any restriction sites and, therefore, could not
be confirmed by restriction digest. S39_K40insS was absent
in 400 ethnically matched control chromosomes. Follow-
ing the recent implication of two new genes (encoding
desmoglein-2 and desmocollin-2) in the pathogenesis of
ARVC,6–8 the proband was also investigated for mutations
in these two genes and was found to be negative.
Clinical and Pathological Findings
Individuals expressing the S39_K40insS mutation showed
an autosomal dominant mode of inheritance of ARVC,
and the mutation cosegregated with the disease phenotype
in the family (fig. 1). In 1990, the proband (II:1) experi-
enced syncope at age 39 years. After a documented episode
of sustained ventricular tachycardia, he was admitted to
the hospital for further diagnostic evaluation and man-
agement. Electrocardiography demonstrated QRS prolon-
gation, T-wave inversion, and late potentials in right pre-
cordial leads. Angiography showed moderate global right
ventricular dilatation and regional wall-motion abnormal-
ities without left ventricular involvement. Sustained mono-
morphic ventricular tachycardia of left bundle branchblock
morphology was induced at electrophysiological study. Bi-
opsy of an endomyocardial sample showed extensive fi-
brofatty replacement of right ventricular muscle and patchy
mononuclear inflammatory infiltrate (fig. 2). These phe-
notypes fulfilled criteria for the diagnosis of ARVC from
the Task Force of the Working Group Myocardial and Per-
icardial Disease of the European Society of Cardiology and
of the Scientific Council on Cardiomyopathies of the In-
ternational Society and Federation of Cardiology.10 An im-
plantable cardioverter-defibrillator was implanted in 1997,
which has since discharged appropriately. The proband’s
skin and hair appeared grossly normal on physical ex-
amination. Individuals II:2 and II:3 (fig. 1) received the
diagnosis of ARVC after cardiac evaluation at their local
medical facilities, on the basis of 12-lead and 24-h electro-
cardiography and echocardiographic abnormalities. Both
subjects II:2 and II:3 have offspring who refused clinical
and genetic screening and who were not included in the
family pedigree. Individual I:1 died at age 70 years of heart
failure and is, therefore, presumed to have been a carrier
of S39_K40insS.
Immunohistochemical Analysis of Intercalated Disk Proteins
To examine the effect of S39_K40insS on the distribution
and expression levels of intercalated disk proteins, immu-
nohistochemistry was performed on the proband’s cardiac
biopsy sample (fig. 3). Myocardial specimens from three
age-matched autopsy subjects who had no clinical history
or pathological evidence of heart disease were subjected
to the same staining protocol and were used as controls.
The ARVC and control myocardium showed comparable
levels of expression of N-cadherin (MIM *114020) and
plakophilin-2, but there was a marked decrease in the
amount of immunoreactive signal at intercalated discs for
plakoglobin, desmoplakin, and the gap-junction protein
Cx43 (MIM *121014) (fig. 3).
Yeast-Two-Hybrid Screening
To investigate the effects of the S39_K40insS mutation on
the binding properties of plakoglobin, yeast-two-hybrid
screening was performed. Both wild-type and mutant
plakoglobin were shown to bind previously identified
binding partners, including desmoplakin and cadherins.
However, the yeast-two-hybrid screen revealed an inter-
action between mutant plakoglobin and two clones that
have not previously been associated with the protein:
TAIP-2 and the sarcoplasmic HRC-BP.
Potential interactions between plakoglobin and TAIP-2
were confirmed by coimmunoprecipitation studies in tran-
siently transfected HEK293 cells. With use of this approach,
both wild-type and mutant plakoglobin were found to
bind TAIP-2 (fig. 4). Potential interactions between plak-
oglobin and HRC-BP were verified by in vitro protein-
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Figure 4. A, Coomassie-blue staining of GST-fused N-terminal
(N), central (mid), and C-terminal (C) domains of HRC-BP and GST.
B, In vitro protein-binding assay, which shows that wild-type plak-
oglobin does not bind any of the three HRC-BP fragments (lanes
1–3), whereas mutant plakoglobin binds all three fragments in
vitro (lanes 4–6). C, Lysates of cell lines induced to express wild-
type (lane 1) and mutant (lane 2) plakoglobin, shown for control
purposes. Coimmunoprecipitation of wild-type PG and TAIP-2 (lane
3), mutant PG and TAIP-2 (lane 4), wild-type PG and V5 vector
(lane 5), mutant PG and V5 vector (lane 6), His Max vector and
TAIP-2 construct (lane 7), and His Max vector and V5 vector only
(lane 8), showing that both wild-type and mutant plakoglobin bind
TAIP-2 in vitro.
Figure 5. A, Four noninduced cell lines (lanes 2, 4, 6, and 8)
that express the endogenous plakoglobin only (82 kDa), compared
with four induced cell lines (lanes 1, 3, 5, and 7) that express
both endogenous plakoglobin (82 kDa) and the mutant form of
plakoglobin, which migrates at ∼90 kDa. Signal for endogenous
plakoglobin is faint in lanes 2, 3, 5, 7, and 8. B, Bands showing
that ubiquitin is present in the cell line expressing the highest
levels of the exogenous construct (from lane 1 in panel A), both
in its free form (8 kDa) and at a form (∼90 kDa) consistent with
its being covalently bound to mutant plakoglobin.
binding assays. Although wild-type plakoglobin did not
bind HRC-BP, mutant plakoglobin was able to bind all
three fragments of the sarcoplasmic protein in vitro (fig.
4).
Subcellular Distribution of Plakoglobin Altered
by S39_K40insS
To elucidate potential pathogenic mechanisms of S39_
iK40insS, HEK293 cells that stably expressed wild-type or
mutant (S39_K40insS) plakoglobin were analyzed by mul-
tiple methods. Western blotting revealed differences in
electrophoretic mobility in plakoglobin expressed by the
transfected cells. In cells expressing wild-type plakoglobin,
one band was observed that matched the predicted size
of plakoglobin (82 kDa) and corresponded to the endog-
enous protein expressed by nontransfected HEK293 cells
(fig. 5A). In contrast, two bands were observed in cells
expressing the S39_K40insS mutation: a lower band (82
kDa) corresponding to native plakoglobin and a higher
band (∼90 kDa) that was the mutant plakoglobin (fig. 5A).
Because cytoplasmic plakoglobin is degraded by the ubi-
quitin-proteasomal system,12 we investigated the possibil-
ity that the mutant protein migrated with an apparent
molecular weight of 90 kDa because it was bound to ubi-
quitin, which has a molecular weight of 8 kDa. Western
blotting with an anti-ubiquitin antibody typically reveals
a smearing band pattern reflecting the abundance of ubi-
quitin and its numerous interactions. However, brief film
exposure revealed two major bands, a lower one that
matched the size of free ubiquitin (∼8 kDa) and a higher
one (∼90 kDa) at the same position seen in the plakoglobin
blot prepared from cells expressing the mutant protein
(fig. 5B).
If S39_K40insS does enhance the interaction of plako-
globin with ubiquitin, the mutant protein might be ex-
pected to show increased cytoplasmic localization. To in-
vestigate the cellular distribution of S39_K40insS plako-
globin as distinguished from that of endogenous plako-
globin, HEK293 cells were transiently transfected to ex-
press wild-type or mutant plakoglobin tagged with GFP.
Transfected cells were counterstained with 4′,6-diamidino-
2-phenylindole (DAPI) to mark nuclei before examination
by confocal microscopy to visualize the GFP-tagged plak-
oglobin. In cells expressing wild-type plakoglobin, the GFP
signal was localized mainly at cell junctions. In contrast,
the signal in cells expressing mutant plakoglobin was
markedly shifted to the cytoplasm (fig. 6). These results
support the hypothesis that mutant plakoglobin is driven
away from cell junctions by its increased association with
the cytoplasmic degradation machinery.
Effects of S39_K40insS on Cell Proliferation and Apoptosis
Apart from its role in cell junctions, plakoglobin is also
known to participate in Wnt-signaling pathways, where
it associates with Tcf/Lef transcription factors13 and regu-
lates functions such as cell proliferation14 and apoptosis.15
To investigate the effects of S39_K40insS on cell prolif-
eration, a CellTiter 96 Cell Proliferation Assay was per-
formed. HEK293 cells stably expressing S39_K40insS plak-
oglobin showed higher proliferation rates than did cells
expressing the wild-type protein; the difference was sta-
tistically significant on the 4th and 5th d of the assay (fig.
7A).
The effect of S39_K40insS on programmed cell death
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Figure 6. Confocal microscopy showing the distribution of wild-type and mutant plakoglobin in transiently transfected HEK293 cells.
The preparations were counterstained with DAPI to show nuclei.
was examined using the CaspACE Assay method. HEK293
cells stably expressing S39_K40insS plakoglobin showed
significantly less caspase activity than did cells expressing
the wild-type protein (fig. 7B), suggesting that there are
lower rates of apoptosis in cells expressing the mutant
protein.
Effects of S39_K40insS on Desmosomal Ultrastructure
Reduced amounts of S39_K40insS plakoglobin at junction-
al sites, potentially related to increased association with
cytoplasmic ubiquitin, might be expected to affect the size
and shape of desmosomes. To investigate this hypothesis,
HEK293 cells stably expressing wild-type or mutant plak-
oglobin were examined by electron microscopy. Mutant
cells formed fewer ( vs. desmosomes per3.2 1.2 6.4 1.9
micrograph; ) and smaller ( vs.P ! .001 0.870.42 2.68
mm per desmosome profile; ) desmosomes0.83 P ! .001
than did wild-type cells. Representative micrographs are
shown in figure 8.
Discussion
We have identified a novel autosomal dominant plako-
globin mutation (S39_K40insS) in a German family af-
fected with ARVC. Recently, an uncommon polymor-
phism in plakoglobin (L697M) was identified to cosegre-
gate with a nonsense mutation in desmoplakin (R1267X)
in a family with early-onset ARVC.16 It has been suggested
that L697M has a negative modifier effect on the cardiac
phenotype in the presence of R1267X.16 In the family pre-
sented here, the L697M polymorphism was not present,
and genotyping of other desmosomal candidate genes—
including those encoding desmoplakin, plakophilin2, des-
moglein2, and desmocollin2—did not reveal additional
mutations. S39_K40insS cosegregated with the disease phe-
notype and was not found in 400 ethnically matched con-
trol chromosomes. It is likely, therefore, that this mutation
is pathogenic rather than a modifying polymorphism.
The index patient was part of a larger cohort of ARVC-
affected patients who were screened for mutations in can-
didate desmosomal genes. The cohort included 1200 in-
dividuals of English origin, 70 individuals of German or-
igin, and 20 individuals of Greek/Cypriot origin. The mu-
tation presented in our study was the only plakoglobin
mutation identified in the cohort. This suggests that plak-
oglobin mutations are uncommon in an unselected pop-
ulation of ARVC-affected patients. In contrast, several mu-
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Figure 7. A, CellTiter 96 Cell Proliferation Assay over the course
of 5 consecutive d. A single asterisk (*) indicates ; aPp .014
double asterisk (**) indicates . B, CaspACE assay. SpecificPp .006
caspase activity was measured in 10 individual wild-type (wt) and
mutant (mut) cultures. An asterisk (*) indicates .Pp .038
tations in the genes coding for desmoplakin, plakophilin2,
desmoglein2, and desmocollin2 were identified in the
cohort.
None of the individuals affected by the S39_K40insS
mutation showed apparent cutaneous abnormalities, in
contrast to abnormalities seen in patients with Naxos dis-
ease.2 This might be explained by the dominant mode of
inheritance of S39_K40insS, because, to date, only homo-
zygous carriers of ARVC-causing recessive mutations have
been documented to manifest hair and skin abnormali-
ties.4 It is likely that the different clinical phenotypes pro-
duced by S39_K40insS and 2057del2 may result from dif-
ferential effects of the mutations on the various plakoglo-
bin-binding partners and the downstream effects on signal-
ing, but this must be analyzed in detail in future studies.
Previous immunohistochemical studies of cardiac tissue
from patients affected with Naxos disease or Carvajal syn-
drome, a cardiocutaneous syndrome caused by a recessive
deletion mutation in desmoplakin, demonstrated mark-
edly decreased localization of intercellular junction pro-
tein at intercalated disks.17,18 To investigate the effects of
S39_K40insS on intercellular junction protein interac-
tions, a myocardial biopsy sample from the proband was
analyzed by immunohistochemistry. N-cadherin and plak-
ophilin-2 were expressed at control levels. As a major com-
ponent of adherens junctions, N-cadherin is not antici-
pated to be affected by S39_K40insS. Plakophilin-2 inter-
acts with desmosomal cadherins through its N-terminal
domain, but this initial interaction is not mediated by
plakoglobin,19 which may explain why S39_K40insS does
not affect the localization patterns of plakophilin-2 at in-
tercalated discs either. In contrast, localization of plako-
globin, desmoplakin, and Cx43 at intercalated disks was
significantly reduced in the ARVC sample. The small size
of the biopsy sample and its preservation in paraffin pre-
vented supportive immunoblotting studies. However, the
fact that some but not all intercalated disc proteins were
affected precludes nonspecific postmortem effects. Further-
more, a similar pattern has been observed in previous
studies.17,18 Plakoglobin binds the N-terminal domain of
desmoplakin and targets it to junctions,20 which may ex-
plain the altered localization pattern of desmoplakin ob-
served in the proband tissue. Diminished accumulation
of Cx43 at intercalated discs has also been observed in
patients with Naxos disease17 and Carvajal syndrome.18
Indeed, it has been suggested that, when adhesive junc-
tions are disturbed, gap junctions cannot be formed and
maintained normally, which may slow electrical conduc-
tion, enhance conduction heterogeneity, and act syner-
gistically with the characteristic structural defects in ARVC
to promote fatal arrhythmias.17
Plakoglobin consists of 13 imperfect armadillo repeats
flanked by N- and C-termini. The first three armadillo re-
peats mediate interactions with desmosomal cadherins.21
Repeats 6–8 are important for interactions between plak-
oglobin and classic cadherins,22 whereas part of the N-
terminal domain and the first armadillo repeat (resi-
dues 109–137) control interactions with a-catenin (MIM
*116805).23 The last three armadillo repeats are not known
to interact with any junctional components but seem to
target the protein to cell borders and stabilize desmosomal
interactions.24 S39_K40insS is predicted to lead to the in-
sertion of a serine residue at position 39 of plakoglobin.
Despite the numerous bonds that plakoglobin establishes
with many adhesion proteins, this part of the protein does
not seem to be involved in any of the above-mentioned
protein-protein interactions. However, a yeast-two-hybrid
screen revealed that plakoglobin bearing the S39_K40insS
mutation bound two novel partners: HRC-BP and TAIP-2.
HRC-BP localizes at the sarcoplasmic reticulum of cardiac
and skeletal muscle cells and is responsible for controlling
Ca2 release.25 One of the first genes known to be associ-
ated with ARVC was RYR2 (MIM *180902), the gene en-
coding the cardiac ryanodine receptor.25 Mutations in RYR2
are thought to permit leakage of Ca2 into the cytoplasm
and thereby trigger arrhythmias.26 It is possible that the
interaction of the mutant plakoglobin with a sarcoplasmic
reticulum protein may result from the altered subcellular
distribution of plakoglobin and have no direct role in the
pathogenesis of ARVC. Alternatively, this interaction could
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Figure 8. Electron micrographs of HEK293 cells stably expressing wild-type or mutant plakoglobin. The arrows indicate adhesive
junctions between adjacent cells.
affect Ca2 homeostasis and thereby promote myocyte in-
jury and/or contribute to electrical instability. Although
TAIP-2 has not been implicated previously in the patho-
genesis of ARVC, there is evidence that links plakoglobin
to the mechanism of apoptosis.15 In any event, these novel
protein interactions must be confirmed in vivo before their
potential role in disease pathogenesis can be established.
The N-terminus plays an important role in determining
stability and degradation of the armadillo proteins. This
region appears to be a target for N- and O-glycosylation27
and is also involved in the ubiquitin-proteasomal–degra-
dation pathway. In the absence of Wnt signaling, plako-
globin associates with GSK-3b through the scaffolding pro-
teins axin and anaphase promoting complex and under-
goes phosphorylation at a number of serine residues on
its N-terminus (residues 22–39), which targets the protein
for ubiquitylation and degradation by the proteasomal
system. In response to Wnt signaling, GSK-3b is prevented
from phosphorylating plakoglobin, which, as a result, be-
comes stabilized, enters the nucleus, and participates in
regulating gene expression.12 There is a fine balance
among the amount of plakoglobin engaged in cell junc-
tions, the fraction of plakoglobin involved in signaling,
and the quantity of plakoglobin that is degraded. A plau-
sible hypothesis is that S39_K40insS disrupts this balance,
perhaps because the presence of an extra N-terminal serine
increases protein-turnover rate. The resultant decrease in
the total amount of plakoglobin may limit its accumula-
tion at cell junctions, leading to impaired intercellular ad-
hesion and development of ARVC. To test this hypothesis,
HEK293 cell lines were transfected to express the mutant
protein. Cells containing the S39_K40insS mutation ex-
pressed plakoglobin with a greater molecular weight than
that of wild-type plakoglobin. This could be explained by
posttranslational modifications, such as glycosylation.
However, confocal microscopy showed that more of the
mutant protein was localized within the cytoplasm and
that less was localized at cell junctions, which could be
related to enhanced ubiquitylation of mutant plakoglo-
bin. The distribution of the mutant protein in the heart or
skin of affected patients must be analyzed in future studies.
We observed that cells expressing mutant plakoglobin
exhibited greater proliferation rates than did cells express-
ing the wild-type protein, suggesting that the S39_K40insS
mutation alters plakoglobin-related signaling pathways.
Charpentier et al.14 reported that plakoglobin suppresses
epithelial proliferation and hair growth in vivo. It is pos-
sible, therefore, that, when normal signaling mediated by
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plakoglobin is disrupted, cell proliferation would be ex-
pected to increase. This mechanism might also explain
the increased proliferation of keratinocytes that lead to
palmoplantar keratoderma in patients with Naxos disease.
Recently, it was shown that suppression of desmoplakin
expression with use of small interfering RNA in atrial my-
ocyte cell lines or in heterozygous desmoplakin-deficient
mice leads to nuclear localization of plakoglobin, reduc-
tion in canonical Wnt signaling through Tcf/Lef transcrip-
tion factors, and increased myocyte apoptosis.28 Increased
myocyte apoptosis has also been reported in patients with
ARVC.29 In the present study, we observed that caspase
activity is reduced in HEK293 cells expressing mutant
plakoglobin, which is consistent with suppressed pro-
grammed cell death, but the significance of this obser-
vation regarding the pathogenesis of ARVC is unclear. It
is possible that the effects of mutant plakoglobin on ap-
optosis differ in HEK293 cells and cardiac myocytes. In
any event, insights about disease mechanisms gained from
investigation of noncardiac myocytes cannot necessarily
be applied to cardiac myocytes. Further studies character-
izing the effects of S39_K40insS on multiple aspects of
cardiac myocyte structure and function are needed.
In conclusion, this study presents, for the first time, an
autosomal dominant mutation in plakoglobin that appears
to be responsible for causing ARVC. Unlike the recessive
deletion mutation in plakoglobin known to cause Naxos
disease, S39_K40insS is not associated with cutaneous ab-
normalities and, therefore, may act through a different
mechanism, perhaps related to altered turnover kinetics of
plakoglobin. Further genetic and molecular studies should
improve our understanding of the disease and perhaps pro-
vide a more accurate diagnostic algorithm and improved
genetics counseling and management strategies.
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